The Russian Ministry of Health has issued a registration certificate for a radiopharmaceutical drug based on radium-223 chloride (223Ra), used to treat castration-resistant prostate cancer with bone metastases and no visceral metastases. The drug was developed by the Federal State Unitary Enterprise (FSUE) «Federal Center of Nuclear Medicine Project Design and Development» of the FMBA of Russia.
“The active ingredient, radium chloride (223Ra), mimics calcium and forms a complex with the bone mineral hydroxyapatite. This allows the radium-223 isotope to selectively target bone tissue, particularly metastatic prostate cancer lesions in the bones. The range of radiation is very short, minimizing the impact on surrounding healthy tissues,” the drug’s instructions explain.
According to center, all preclinical and clinical trials were conducted at leading global centers, confirming the drug’s effectiveness. Additionally, the quality and safety of the drug are ensured by the raw materials supplied by FMBA Russia’s long-standing and reliable partner, the State Scientific Center “Research Institute of Atomic Reactors.”
